Taken for 28 consecutive days, followed by a 14-day rest. Initial dose can be decreased according to patient's condition. Lower limit: 40 mg. Adult BSA ≥1.5 m2 Initially 60 mg bd, 1.25 to <1.5 m2 Initially 50 mg bd, <1.25 m2 Initially 40 mg bd.
Provide a min washout period of 7 days when other fluoropyrimidine-group anticancer drugs or flucytosine are used after TS-One w/drawal. Provide an appropriate washout period when TS-One is used after w/drawal of other fluoropyrimidine-group anticancer drugs or flucytosine. Carefully monitor patients w/ bone marrow suppression; diarrhea; dehydration. Prevent or correct at onset dehydration & any associated electrolyte disturbances. Closely monitor renal parameters & hepatic function. Increased risk of fluoropyrimidine-related toxicity in patients w/ DPD deficiency. Testing for DPD deficiency prior to treatment initiation is recommended. Avoid appearance or aggravation of infection or bleeding tendency. Potential gonadic effects. May cause or aggravate interstitial pneumonia. Reactivation of hepatitis B. Reports of acute leukemia or myelodysplastic syndrome; cerebral infarction. Risk of ocular toxicity. Concomitant use w/ oral coumarin-derivative anticoagulant. Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose/galactose malabsorption. Patients w/ bone marrow depression; infectious disease; abnormal glucose tolerance; current or previous history of interstitial pneumonia; current or previous history of heart disease; GI ulcer or hemorrhage; renal &/or hepatic impairment. Elderly. Discontinue breastfeeding. Safety in low birth wt infants, neonates, infants or childn has not been established.
Sign Out
